Description
Introduction to Cytarabine Injection:
Cytarabine Injection (Arasid 500mg Injection) is an anticancer medicine used to treat certain types of blood cancers, including leukemia. It belongs to a class of chemotherapy medicines and may also be used for other conditions as determined by your doctor. It is sometimes used together with other medicines as part of combination chemotherapy.
This 500mg Injection is administered into a vein or under the skin by a healthcare professional. Your doctor will decide the appropriate dose and how often you need it, depending on your specific condition — this may change over time. It’s important to take it exactly as your doctor has advised, since taking too much or using it incorrectly can cause serious side effects. Benefits may take several weeks or months to become noticeable, so treatment should not be stopped without your doctor’s guidance.
Before starting treatment, your doctor may review your complete medical history, including any existing liver or kidney conditions, current medications, and previous cancer treatments. Regular blood tests are often required throughout treatment to monitor blood cell counts and organ function.
Uses of Cytarabine Injection:
- Blood cancer (leukemia)
Benefits of Cytarabine Injection :
In Blood cancer
Blood cancer, also called leukemia, is a cancer of the blood-forming tissues that reduces the body’s ability to fight infection. This 500mg Injection kills or stops the growth of cancer cells and also prevents their further multiplication. It is a powerful and potentially toxic medication, so it’s important to discuss the risks and benefits with your doctor before starting treatment. You should avoid drinking alcohol during this treatment and drink plenty of water to stay well hydrated.
Mechanism of Action of Cytarabine Injection :
Arasid 500mg Injection impedes the development of DNA and RNA of the cancer cells by subbing their structure blocks. It keeps the cancer cells from developing and duplicating.

Reviews
There are no reviews yet.